ICCMICCMHealthcare · Medical Devices

ICCM Stock Forecast: IceCure Medical Ltd. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$0.84
−15.65% on the day

The median 12-month analyst price target for IceCure Medical Ltd. is $29. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 30 of 100 as at 21 Nov 2026 — in the lower half.

Market cap
$4.6M
Ticker Nerd rank
30/ 100
Median analyst target
$29
Analysts covering
3
Revenue$907K+72.8% y/y
Operating income−$4.4M
Net income−$4.5M
Free cash flow−$3.9M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+15.2%
1M
−19.9%
YTD
−95.4%
1Y
−95.7%
From 52W high
−96.2%
From 52W low
+23.5%
$1
$22
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores IceCure Medical Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
30/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
77
Revisions
69
Volatility
46
Accruals
44
Momentum
24
Issuance
12
Quality
10
Value
2

Growth (77): Sales and profits are climbing, and climbing faster than before.

Value (2): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

ICCM stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ICCM, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30Jan 26Apr 26Jul 26Oct 26ICCMHigh $30Median $29Low $28

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says3 analysts
3
Buy
0
Hold
0
Sell
$28
Low
$29
Median
$30
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
14 May 2026Maxim GroupMaintainsBuy$3.00 → $1.00
7 Oct 2025HC Wainwright & Co.MaintainsBuy—
15 Aug 2025HC Wainwright & Co.MaintainsBuy—
29 May 2025HC Wainwright & Co.ReiteratesBuy—
28 Mar 2025HC Wainwright & Co.ReiteratesBuy—
27 Nov 2024HC Wainwright & Co.ReiteratesBuy—
8 Nov 2024HC Wainwright & Co.ReiteratesBuy—
12 Sept 2024HC Wainwright & Co.ReiteratesBuy—
21 Aug 2024HC Wainwright & Co.MaintainsBuy—
2 July 2024HC Wainwright & Co.ReiteratesBuy—
5 June 2024HC Wainwright & Co.ReiteratesBuy—
29 May 2024HC Wainwright & Co.ReiteratesBuy—
16 Apr 2024HC Wainwright & Co.ReiteratesBuy—
4 Apr 2024HC Wainwright & Co.ReiteratesBuy—
20 Mar 2024Alliance Global PartnersMaintainsBuy—
20 Mar 2024HC Wainwright & Co.ReiteratesBuy—
5 Mar 2024HC Wainwright & Co.ReiteratesBuy—
29 Nov 2023HC Wainwright & Co.ReiteratesBuy$3.00
6 Sept 2023HC Wainwright & Co.ReiteratesBuy$3.00
15 Aug 2023Alliance Global PartnersMaintainsBuy$4.25 → $4.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for ICCM.

Market Radar

This page is one stock. Monday covers all of them.

ICCM appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

ICCM vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, IceCure Medical Ltd. returned −95.7% against +6.9% for the S&P 500, dividends included.

ICCM vs S&P 500, last 12 monthsTotal return, rebased to 100
020406080100120Jan 26Apr 26Jul 26Oct 26ICCMS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ICCM analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
1.1×

Cheaper than 63% of US stocks

Price / book
0.5×

Cheaper than 86% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
27.9%

Higher than 31% of US stocks

Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−190.7%

Higher than 8% of US stocks

Return on assets
−73.4%

Higher than 4% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • IceCure Medical Ltd. has a market value of $4.6M.

  • Revenue in the twelve months to 30 June 2026: $3.9M. The latest quarter grew 72.8% year on year.

  • Net income over the same four quarters: −$16.9M, a −427.7% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$15.9M.

  • Shares outstanding: 3.4M.

  • IceCure Medical Ltd. employs 67 people — $59K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

ICCM and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
ICCMIceCure Medical Ltd.$4.6M30
INBSIntelligent Bio Solutions, Inc.$4.6M21
WOKWORK Medical Technology Group Ltd.$4.9M16
BMRABiomerica, Inc.$5.0M11
BDMDBaird Medical Investment Holdings Ltd.$5.1M59
POASPhaos Technology Holdings (Cayman) Ltd.$5.1M2
NVNOenVVeno Medical Corp.$3.6M28

Take a look at ICCM’s peer groups, ranked by the model: healthcare stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own IceCure Medical Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about ICCM

What is the ICCM stock price forecast for 2026-2027?

The median 12-month analyst price target for IceCure Medical Ltd. is $29, with estimates ranging from $28 to $30. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ICCM stock a buy right now?

Of the 3 analysts covering IceCure Medical Ltd., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks IceCure Medical Ltd. 30 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ICCM?

As at 21 Nov 2026, IceCure Medical Ltd. ranks 30 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (77 of 100).

Will ICCM stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts is $29, and Ticker Nerd's factor model ranks IceCure Medical Ltd. 30 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ICCM stock forecast for 2030?

No analyst covering IceCure Medical Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ICCM are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $28 to $30 over the next 12 months.

How has ICCM stock performed over the past year?

IceCure Medical Ltd. returned -95.7% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does IceCure Medical Ltd. do?

IceCure Medical Ltd. is a commercial-stage medical device company focused on developing and marketing minimally invasive cryoablation systems for tumor treatment. Its core products use liquid nitrogen-based technology to destroy benign and cancerous tumors by freezing them, offering physicians an alternative to traditional surgical removal.

Company

About IceCure Medical Ltd.

IceCure Medical Ltd. is a commercial-stage medical device company focused on developing and marketing minimally invasive cryoablation systems for tumor treatment. Its core products use liquid nitrogen-based technology to destroy benign and cancerous tumors by freezing them, offering physicians an alternative to traditional surgical removal. The company’s portfolio includes the ProSense system and associated disposable CryoProbes, which are used in procedures across women’s health and interventional oncology. IceCure Medical also supports broader ablation applications in areas such as breast, kidney, bone, and lung cancer, with products designed for use in office-based, operating room, and imaging-guided settings. Based in Caesarea, Israel, IceCure Medical serves healthcare providers in multiple international markets and plays a niche role in expanding access to minimally invasive tumor care.

CEO Mr. Eyal Shamir · 67 employees · Israel · https://www.icecure-medical.com